Comparative Pharmacology
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus INDERIDE LA 120 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus INDERIDE LA 120 50.
BETAXOLOL HYDROCHLORIDE vs INDERIDE LA 120/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
10-20 mg orally once daily; maximum 20 mg/day.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
None Documented
None Documented
Terminal elimination half-life: 14–22 hours (mean 16 hours); sufficient for once-daily dosing in hypertension; prolonged in renal impairment.
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Renal: 80% (as unchanged drug and inactive metabolites), Fecal: 20%
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Category C
Category C
Beta-Blocker
Beta-Blocker/Diuretic Combination